Objective: To determine whether the use of salbutamol, in a helium-oxygen mixture (80:20), can modify outcome and risk of hospitalization of pediatric patients.
Introduction
The first-line treatment for some childhood obstructive pulmonary diseases is fundamentally based on the administration of inhaled bronchodilators. Within this context, it is believed that, in patients with an important degree of airway obstruction, deposition of aerosol medication is often difficult to accomplish and, consequently, a minor clinical response to the use of such medication is expected. Thus, a gas mixture composed of helium and oxygen (Heliox ® ) has been used as a promising therapeutic alternative in these obstructive diseases resulting from many different All patients were prescribed bronchodilator solutions, according to the unit's routine care. The medical team selected the patients who would receive Heliox ® , whereas the research team was limited to follow outcome of patients (throughout their stay in the observation room). The identification of patients receiving conventional therapy (selected by severity, sex, and age) was the responsibility of the research team, which also followed these patients throughout their stay in the observation room. The population selected as a control was obtained sequentially for every case using Heliox ® , always trying to identify the next patient to be treated in the unit with the clinical characteristics established for inclusion in the study.
The use of Heliox ® was established by the medical team, in a process of convenience sampling, without any intervention by the research team. The research team established the criteria for composition of the control group (similarity matching).
In both populations, patients with congenital heart disease, bronchopulmonary dysplasia, bronchopneumonia, tracheostomized patients or patients with facial dysmorphism were excluded.
For study purposes, the diagnosis of acute asthmatic crisis was established by the presence of recurrent respiratory symptoms (coughing, wheezing, and/or chest tightness) associated with previous, unequivocal clinical response to inhaled bronchodilator therapy. 1 The diagnosis of viral bronchiolitis considered patients under 18 months of age, with first clinical manifestation of obstructive airway disease (wheezing and/or rales associated with signs of respiratory distress). 3 All patients had prodromal illness suggestive of upper airway viral infection (evolution not exceeding 72 h) and chest radiological investigation supporting the hypothesis of viral bronchiolitis, established by a pediatric radiologist not participating in the study.
Administration of medication
Once patient eligibility clinical criteria were met and the inhaled bronchodilator therapy was indicated, the patients received sequentially, at 20-min intervals, until six nebulization cycles were completed (2-h period): salbutamol 0.15 mg/kg/dose (maximum 5 mg). The nebulized drug was driven either by a helium-oxygen mixture (Heliox ® ) at a ratio of 80:20 (cases) or 100% oxygen (controls). etiologies. However, over the last 20 years, this gas mixture has been more frequently used in bronchial asthma and acute viral bronchiolitis, both in the emergency department and intensive care unit. [1] [2] [3] Helium has a threefold lower density than room air or 100% oxygen. The low density of helium can turn a turbulent airflow into a laminar flow and, consequently, decrease airway resistance, resulting in decreased inspiratory pressure and work of breathing. 4 Moreover, helium increases carbon dioxide diffusion and can improve alveolar ventilation. 5 These properties make Heliox ® an alternative to be considered in the treatment of patients with asthma and other conditions of severe airway obstruction.
Kim et al., 4 using Heliox ® -driven albuterol, showed better clinical response in the treatment of pediatric patients with acute severe asthma, when compared to oxygen. Similarly, a 70:30 helium-oxygen mixture has been used for treatment of acute viral bronchiolitis. 6 Martinón-Torres et al., 7 in a clinical trial, observed favorable outcome (improvement in clinical score, heart rate, and respiratory rate, and decreased length of stay in intensive care unit) in 19 patients who used the gas mixture (Heliox ® ). All patients had bronchiolitis (moderate-to-severe intensity) and their controls were managed conservatively (supportive measures associated with oxygen-driven nebulized epinephrine).
Although bronchial asthma and acute viral bronchiolitis are prevalent diseases, accounting for a significant number of pediatric hospitalizations, both in the emergency department and intensive care unit, the use of Heliox ® has been little studied in our field. 8, 9 Therefore, the present study was designed to determine whether the use of salbutamol, administered intermittently, in a frequent manner, and driven by a helium-oxygen mixture (80:20), can modify outcome and risk of hospitalization in a group of pediatric patients.
Methods

Study design
This is a controlled cohort study including patients aged 2 months to 12 years. All patients had a clinical diagnosis of acute asthmatic crisis or viral bronchiolitis established by the medical team providing care to each patient. Intensity should be from moderate to severe, as measured by the pulmonary index (PI) for obstructive disease. 10 Scores > 8 were considered eligible. 2, 11 All patients with asthmatic crisis and acute viral bronchiolitis assisted in the emergency department who received bronchodilators driven by Heliox ® were considered for inclusion in the study. Controls were patients with the same diagnoses (assisted in the emergency department), matched for similarities (physical and temporal), who received conventional bronchodilator therapy (with oxygen). For study purposes, the need to stay in the observation room and the need for supplemental oxygen were evaluated at 6 and 12 h. Additionally, the need for hospitalization (after 12 h) and the need for admission to pediatric intensive care unit were compared between groups. The general characteristics of the sample were described as mean and standard deviation. Quantitative data were compared using Student's t test. Differences < 95% were considered to be Compared to the conventional technique of administration of inhaled bronchodilator drugs, the use of the gas mixture showed a lower risk of staying in the observation room after 6 and 12 h of treatment. Likewise, the gas mixture also showed a lower risk of requiring supplemental oxygen, mainly in the first 6 h of treatment.
These more favorable responses, observed in the first hours of treatment, may be related to an optimization of drug deposition within the airways. The benefits resulting from the physical properties of gas mixtures balanced with up to 40% helium are well described in the literature. 12 Within this range (21 to 40% oxygen), it is possible to preserve the benefits of a gas mixture of lower density and lower coefficient of resistance while maintaining a more constant gas flow through the airways. It is therefore possible that patients with severe obstructive conditions, secondary to bronchospasm, debris or cellular residues, may benefit from this therapy. 13 Although the physical properties of helium are well known for decades, its ability to drive bronchodilator substances has not always been accepted. Only in recent years this ability has been clearly evidenced, associated with the fact that the control of gas flow and concentration requires specifically adjusted equipment. 5 Although a fixed concentration of the gas mixture (80:20) was administered to all patients, the device used (Heliomix ® ) allowed adjustments in helium and oxygen delivery. This is important because some studies employ techniques of continuous nebulization when using the gas to drive nebulizer therapy. 14 Thus, Heliomix ® could ensure up to 40% oxygen in the mixture, or even deliver 100% oxygen if hypoxemia was determined.
In our study, we decided to test some benefits resulting from the early administration of Heliox ® (in the first six nebulization cycles, performed within the first 2 h of treatment).
This strategy was devised for some reasons. The first was based on the principle of not changing the routine treatment employed in the department concerning administration of bronchodilator substances (both in asthma and bronchiolitis), considering dose and administration intervals. The second resulted from the observation of some discomfort in using the closed system with adjustable face mask, mainly in younger patients and for longer periods of time.
Although studies using this strategy can be found in the literature, 15, 16 we believe that, even for a 2-h period,
we would have great difficulty in maintaining the nebulizer system adapted in a continuous manner to the patient's face in a significant number of cases.
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Our study has some limitations. The most important one is related to the small sample size. We cannot confidently establish that the lack of benefits found after 6 h has not been determined by the combination of an insufficient number of patients with a less marked effect of the gas mixture. Taking into consideration the significant differences found between groups at 6 h, we believe that this therapy is useful in these patients.
Regarding the use of a bronchodilator substance 
